News | November 25, 2023
DxVx plans to make a license-in agreement of OVM-200
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
Extraintestinal pathogenic E. coli (ExPEC) has been identified as the leading bacterial cause of sepsis
General Medicine grows 5% and Vaccines 10% led by Shingrix
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
2023 Nobel laureates discovered how pseudouridine could make mRNA suitable for vaccines
The companies plan to start a pivotal Phase 3 trial in the coming months
The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer
The vaccine further advances Pfizer’s vaccine portfolio and builds on more than 20 years of expertise and knowledge in the prevention of meningococcal disease
New effective carrier systems for drug delivery in different dosage applications including oral, topical & parenteral
Punit has more than 20 years of experience in the generics and branded pharmaceutical marketplace
Subscribe To Our Newsletter & Stay Updated
